What's preventing insurers from covering the specialized care of patients with nano-rare mutations, thereby expanding access to available treatment options? Is it the population size, cost, or perceived risk? Given that the initial discovery of nano-rare mutations is relatively recent, paving the way for this population requires a nuanced approach to overcome various obstacles. Alan Lotvin, M.D., CEO and co-founder of Sequel Med Tech, and former president of CVS Caremark, conceptualizes these hurdles.
On This Episode We Discuss:
2:20 - Alan used to be an interventional cardiologist in New Jersey
4:45 - Why Alan left cardiology and eventually pursued specialty pharma
9:30 - Many medications that specialty pharmacies provide need special handling, storage, and administration
12:30 People aren’t taking their statins, cholesterol-lowering drugs, why not?
18:02 Discussing the defined thresholds needed to qualify various drugs and procedures
25:13: Specialty pharmacies are for “hard to handle” drugs
26:40 How should drugs be marketing ethically?
31:15 What a Pharmacy Benefit Manager (PBM) does
37:56 Alan helped build CVS Caremark as President
41:55 Alan’s Interest in n-Lorem and what’s preventing insurers from covering the specialized care of patients with nano-rare mutations?
5 сен 2024
